Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Hybrid core-shell particles for mRNA systemic delivery

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      Laboratoire d'automatique, de génie des procédés et de génie pharmaceutique (LAGEPP); Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-École Supérieure de Chimie Physique Électronique de Lyon (CPE)-Centre National de la Recherche Scientifique (CNRS); Institut de Chimie et Biochimie Moléculaires et Supramoléculaires (ICBMS); Université de Lyon-Université de Lyon-École Supérieure de Chimie Physique Électronique de Lyon (CPE)-Institut National des Sciences Appliquées de Lyon (INSA Lyon); Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut de Chimie - CNRS Chimie (INC-CNRS)-Centre National de la Recherche Scientifique (CNRS); Universiteit Gent = Ghent University = Université de Gand (UGENT); Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL); Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS); Centre Léon Bérard Lyon; Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU); Hospices Civils de Lyon (HCL); ANR-16-IDEX-0005,IDEXLYON,IDEXLYON(2016); ANR-17-ENM3-0008,RESOLVE,SuppRESsion of immunopathology by nanOparticle deLiVEry of mRNA to monocytes(2017)
    • Publication Information:
      CCSD
      Elsevier
    • Publication Date:
      2023
    • Collection:
      HAL Lyon 1 (University Claude Bernard Lyon 1)
    • Abstract:
      International audience ; mRNA based infectious disease vaccines have opened the venue for development of novel nucleic acids-based therapeutics. For all mRNA therapeutics dedicated delivery systems are required, where different functionalities and targeting abilities need to be optimized for the respective applications. One option for advanced formulations with tailored properties are lipid-polymer hybrid nanoparticles with complex nanostructure, which allow to combine features of several already well described nucleic acid delivery systems. Here, we explored hyaluronic acid (HA) as coating of liposome-mRNA complexes (LRCs) to investigate effects of the coating on surface charge, physicochemical characteristics and biological activity. HA was electrostatically attached to positively charged complexes, forming hybrid LRCs (HLRCs). At different N/P ratios, physico-chemical characterization of the two sets of particles showed similarity in size (around 200 nm) and mRNA binding abilities, while the presence of the HA shell conferred a negative surface charge to otherwise positive complexes. High transfection efficiency of LRCs and HLRCs in vitro has been obtained in THP-1 and human monocytes derived from PBMC, an interesting target cell population for cancer and immune related pathologies. In mice, quantitative biodistribution of radiolabeled LRC and HLRC particles, coupled with bioluminescence studies to detect the protein translation sites, hinted towards both particles' accumulation in the hepatic reticuloendothelial system (RES). mRNA translated proteins though was found mainly in the spleen, a major source for immune cells, with preference for expression in macrophages. The results showed that surface modifications of liposome-mRNA complexes can be used to fine-tune nanoparticle physico-chemical characteristics. This provides a tool for assembly of stable and optimized nanoparticles, which are prerequisite for future therapeutic interventions using mRNA-based nanomedicines.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/36442614; PUBMED: 36442614
    • Accession Number:
      10.1016/j.jconrel.2022.11.042
    • Online Access:
      https://hal.science/hal-04082346
      https://hal.science/hal-04082346v1/document
      https://hal.science/hal-04082346v1/file/Andretto%20V%202023%20J%20Contr%20Rel.pdf
      https://doi.org/10.1016/j.jconrel.2022.11.042
    • Rights:
      info:eu-repo/semantics/OpenAccess
    • Accession Number:
      edsbas.9C4EB7CA